Cell Therapeutics Inc. (CTIC)
Oncology Corporate Profile

(Reuters) September 3, 2010 - Celldex Therapeutics Inc said its partner Pfizer ended the deal to co-develop Celldex's cancer vaccine, its lead product, as the program was no longer a strategic priority for the drug giant.

(Los Angeles Times) August 31, 2010 - The Obama administration on Tuesday asked a federal judge to lift a restraining order that it says could undercut U.S. government funded embryonic stem cell research.

(Oregon State University) August 30, 2010 - New research on how skin cancer begins has identified adjacent cancer cells that scientists are calling “co-conspirators” in the genesis of melanoma, in findings that could someday hold the key to predicting, preventing and stopping this hard-to-treat cancer before it spreads.

(AACR) August 25, 2010 - The American Association for Cancer Research (AACR), the world's oldest and largest cancer research organization, reiterates its support for the responsible conduct of human embryonic stem cell research that, up until this week, was funded by the National Institutes of Health (NIH) and expresses concern that the recent Federal District Court injunction to block federal funding for human embryonic stem cell research is a setback for scientific discovery.

(Mayo Clinic) August 24, 2010 - To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer.

(Los Angeles Times) August 24, 2010 - A federal judge blocks U.S. funding for all projects involving the use of material from human embryos.

(ASH) August 18, 2010 - Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology.

(AACR) August 18, 2010 - The American Association for Cancer Research is currently accepting nominations for awards recognizing excellence in cancer research, to be presented at the 102nd AACR Annual Meeting 2011, held in Orlando, Fla., from April 2 to 6.

(ScienceBlog) August 17, 2010 - Adult stem cells that are vital for airway repair in the lung but that persist in areas where pre-cancerous lesions are found are associated with a poor prognosis in patients who develop cancer, even those with early stage disease, researchers at UCLA’s Jonsson Comprehensive Cancer Center have found.

(HHMI) August 15, 2010 - Therapeutic cells, such as those implanted in the body to battle cancer or replenish devastated populations of stem cells, may someday be able to carry their own life-support packets.

(BioCancell) August 15, 2010 - BioCancell Therapeutics Inc. today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to BioCancell's lead drug-candidate, BC-819 (currently in clinical trial stages), for use in treating pancreatic cancer.

(Yahoo! Finance) August 16, 2010 - Cell Therapeutics, Inc. announced today that it has received notice that the European Medicines Agency has validated the expanded Pediatric Investigation Plan that CTI filed in July for pixantrone for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

(ScienceBlog) August 12, 2010 - A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer.

(ABC News) August 11, 2010 - Treating tumors with salmonella bacteria can induce an immune response that kills cancer cells, scientists have found -- a discovery that may help them create tumor-killing immune cells to inject into patients.

(Reuters) August 12, 2010 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma (RCC).

(UCLA) August 9, 2010 - Scientists from UCLA's California NanoSystems Institute and Korea's Yonsei University have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field.

(ScienceBlog) August 3, 2010 - New technologies for the diagnosis of cancer are rapidly changing the clinical practice of oncology. As scientists learn more about the molecular basis of cancer, the development of new tools capable of multiple, inexpensive biomarker measurements on small samples of clinical tissue will become essential to the success of genetically informed and personalized cancer therapies.

(Cell Therapeutics, Inc.) August 4, 2010 - Cell Therapeutics, Inc. today announced it has filed for a Special Protocol Assessment with the U.S. Food and Drug Administration for the design of its new phase III trial of pixantrone for patients with relapsed or refractory aggressive B-Cell non-Hodgkin's lymphoma.

(MarketWatch) August 3, 2010 - ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC).

(Reuters) August 2, 2010 - Pancreatic tumor cells use fructose to divide and proliferate, U.S. researchers said on Monday in a study that challenges the common wisdom that all sugars are the same.

(UCLA Jonsson CCCC) July 29, 2010 - UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of more effective targeted treatments for the disease.

(Yahoo! Finance) July 29, 2010 - Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE® (bortezomib) in patients with relapsed/refractory mantle cell lymphoma (MCL).

(UNC) July 27, 2010 - A normally benign protein found in the human body appears to be able – when paired with nanoparticles – to zero in on and kill certain cancer cells, without having to also load those particles with chemotherapy drugs.

(ACCC) July 27, 2010 - On July 27, 2010, the Association of Community Cancer Centers (ACCC) submitted comments to the Centers for Medicare & Medicaid Services’ (CMS) about the opening of a national coverage analysis (NCA) for autologous cellular immunotherapy of treatment of metastatic prostate cancer.